Novel Microdevices awarded up to $13.8M for STD detection

Novel Microdevices, Inc., a Baltimore-based developer of an innovative molecular diagnostics platform, announced Tuesday that CARB-X has awarded the company up to $13.8 million in non-dilutive funding to develop its next-generation rapid molecular test for the diagnosis of sexually transmitted bacterial infections, including Chlamydia trachomatis and Neisseria gonorrhoeae. Novel's new device will also detect antibiotic-resistant gonorrhea, including those strains resistant to the only effective ...

To purchase a reprint of this article, contact reprints@thedailyrecord.com.